A Phase II Study of Atezolizumab Immunotherapy in Patients with Operable, Untreated Non-Small Cell Lung Cancer

Full Title

ML39236: A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer


Atezolizumab is an immunotherapy drug. It boosts the power of the immune system to find and kill cancer cells by blocking PD-L1, a protein which may help cancer cells escape detection by the immune system. Atezolizumab is used to treat bladder cancer and previously treated metastatic (stage IV) non-small cell lung cancer (NSCLC).

In this study, researchers are assessing the safety and effectiveness of giving atezolizumab before surgery for patients with resectable stage IB-III NSCLC that has not yet been treated. All enrolled patients will receive two doses of atezolizumab before surgery. If the drug works against their tumor and is well tolerated, they will have the option to receive more atezolizumab after lung cancer surgery. Atezolizumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage IB, II, or III NSCLC that has not yet been treated and will be surgically removed.
  • Patients may not have previously received an inhibitor of PD-1 or PD-L1.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Jamie Chaft at 646-888-4545.